Rapid diagnostics healthcare technology company Lumos Diagnostics will be a hot IPO to watch. It has great product, fantastic leadership, wider market reach and accelerating its expansion. Below are key summary:
Founded in 2015
Core Product is a world-first finger prick blood test called FebriDx, which can indicate if a person has a bacterial or viral infection within 10 minutes i
Other main offering is point-of-care diagnostics tests and proprietary digital reader platforms
Revenue : In the six months to December 31, Lumos’ revenue tripled to $11.5 million, compared with the previous corresponding period
Market reach: Australia, UK, Germany, Canada , US
Pre-ipo: In October, the company closed a $25 million funding round
Recent deal: a deal with Italian multinational diagnostics biotech DiaSorin to manufacture and launch its immunoassay point-of-care platform.
Key backing: Perennial Value Management and Ellerston Capital
